Knee joint, back, neck and shoulder pains, in descending order, were the commonest type of joint complaints, although not statistically significant (P > 0.05) in subjects with and without joint hypermobility. It was also observed that the left side, at all the sites, was slightly more hypermobile in comparison to the right side in hypermobile subjects. The prevalence of joint hypermobility is not uncommon among young Kuwaiti adults, and was comparable to the data published in other Asian-Pacific Alectinib price regions. General
practitioners should therefore be familiar with the condition and its clinical associations, while assessing musculoskeletal complaints. “
“Coexistence of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is rare. Tumor necrosis factor (TNF) inhibitor has been highly successful in controlling inflammation in many patients with AS or RA. Rituximab, which is a chimeric anti-CD20 monoclonal antibody, has been proven effective in RA. Whether rituximab may be effective in AS is presently unclear. Here we report the 18 months follow-up result of a coexisting AS and RA TNF inhibitor failed patient that was treated successfully with rituximab. “
“We report a 29-year-old Malay man who had pulmonary manifestations as an initial presentation for systemic lupus erythematosus. He had prolonged hospitalization and was treated with selleck chemical intensive
care therapy with immunosuppressants. “
“To investigate the differences of B lymphocyte stimulator (BlyS) DCLK1 level and frequency of lymphocytes between sero-negative and sero-positive
rheumatoid arthritis (RA) patients. Sixty-nine RA patients were enrolled into this study and their clinical data were recorded. The BlyS levels in plasma, frequency of T and B lymphocytes, as well as T-helper (Th) subgroups were compared between sero-negative and sero-positive RA patients. Furthermore, the correlations between clinical features and immunological features were analyzed. The plasma BlyS level in sero-negative RA was higher compared to the sero-positive RA patients (1.73 ± 1.71 vs. 0.99 ± 0.59 ng/mL, P < 0.05) and osteoarthritis (OA) patients (1.73 ± 1.71 vs. 0.59 ± 0.12 ng/mL, P < 0.05). Plasma BlyS level was correlated with disease activity score (DAS-28, erythrocyte sedimentation rate and C-reactive protein), but had no correlation with the titers of rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies. The patients with more advanced changes in X-rays had high plasma BlyS levels. No significant differences in the frequency of T lymphocytes, Th subpopulations and B lymphocytes in peripheral blood were observed between sero-negative and sero-positive RA patients. Plasma BlyS level was correlated with disease activity and radiological progress, which indicates that plasma BlyS level may become a useful biological marker to reflect DAS and to predict RA prognosis.